Novartis AG Common Stock (NVS)
Stock · NYSE · Health Care
$150.59as of 10/16/2026
Price chart
Active signals
NVS Signal Track Record
How signals performed across all stocks →What NVS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 27 | +4.3% | 63% | September 1, 2026 |
| Bollinger Band Breakdown | 26 | +1.6% | 58% | September 8, 2026 |
| Bollinger Band BreakoutActive now | 23 | +3.7% | 74% | July 2, 2026 |
| 200-Day Moving Average TouchActive now | 22 | +1.5% | 64% | May 13, 2025 |
| Any 20-session window (baseline) | +1.2% | 57% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthri…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 75,267
- Website
- www.novartis.com/
Fundamentals
- 1-day range
- $149.64$151.83
- Market cap
- $294.26B
- P/E (trailing)
- 21.21
- P/E (forward)
- 15.34
- EPS (trailing)
- $6.62
- Dividend yield
- 3.72%
- Beta
- 1.35
- Avg. volume
- 1.97M
- Ex-dividend date
- March 11, 2026
- Dividend pay date
- March 16, 2026
Forecasts
11 analyst ratings
Novartis AG Common Stock Competitors
Chosen by industry and closest market cap.
- NVSNovartis AG Common Stock$150.62▲ 0.16%Market cap $294.26BP/E 21.21$97.05$132.68
- MRKMerck & Company Inc. Common Stock (new)$145.95▲ 0.52%Market cap $317.05BP/E 112.60$82.01$156.92
- AZNAstraZeneca PLC Ordinary Shares$165.41▼ 0.76%Market cap $249.78BP/E 24.19$11,404$15,730
- NVONovo Nordisk A/S Common Stock$38.83▼ 0.99%Market cap $203.55BP/E 9.74$224.25$409.95
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
- ABBVAbbVie Inc. Common Stock$285.42▲ 0.71%Market cap $430.95BP/E 79.39$190.75$285.4
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NVS Novartis AG Common Stock | $294.26B | 21.21 | $150.62 | ▲ 0.16% | $97.05$132.68 |
| MRK Merck & Company Inc. Common Stock (new) | $317.05B | 112.60 | $145.95 | ▲ 0.52% | $82.01$156.92 |
| AZN AstraZeneca PLC Ordinary Shares | $249.78B | 24.19 | $165.41 | ▼ 0.76% | $11,404$15,730 |
| NVO Novo Nordisk A/S Common Stock | $203.55B | 9.74 | $38.83 | ▼ 0.99% | $224.25$409.95 |
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
| ABBV AbbVie Inc. Common Stock | $430.95B | 79.39 | $285.42 | ▲ 0.71% | $190.75$285.4 |
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Ramsay Générale de Santé (ENXTPA:GDS) Is Back In The SpotlightYahoo · 10/10/2026
- Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell RightsYahoo · 10/10/2026
- Melexis (ENXTBR:MELE) Stock May Be 27% Undervalued As Cash Flow Holds UpYahoo · 10/9/2026
- Cancer Stocks to Consider as Oncology Innovation AcceleratesYahoo · 10/9/2026
- Suominen’s financial reporting in 2027Yahoo · 10/9/2026
- Barclays downgrades 2 European airline stocks into September quarter resultsYahoo · 10/9/2026
- Former Highflier Argenx Plummets On A Surprise Setback In Sjogren'sYahoo · 10/8/2026
- Argenx Stock Sinks on Scrapped Autoimmune Drug Trial. Why the Selloff Is Overdone.Yahoo · 10/8/2026
- Celldex Prepares For 2027 FDA Submission for Chronic Skin Diseasebenzinga · 9/22/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 147.23M
- Total value held
- $21.60B
- Institutional holders
- 1572
- Unknown13.89M
- Unknown8.53M
- Unknown8.11M
- Unknown7.57M
- Unknown6.97M
- Unknown6.53M
- Unknown5.43M
- Unknown4.96M
- Unknown3.41M
- Unknown2.95M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Novartis Signals Progress With Dual Hives Approval and MS Data
Novartis is drawing attention for its recent dual approval in hives treatment and new data related to multiple sclerosis. These developments highlight the company's ongoing pipeline progress and clinical milestones. The stock is currently trading near the upper end of its 52-week range, reflecting recent positive momentum.
Novartis Signals Progress With Dual Hives Approval and MS Data. Novartis is drawing attention for its recent dual approval in hives treatment and new data related to multiple sclerosis. These developments highlight the company's ongoing pipeline progress and clinical milestones. The stock is currently trading near the upper end of its 52-week range, reflecting recent positive momentum.